Latest news with #IGI
Time of India
3 days ago
- Business
- Time of India
Glenmark's blood cancer drug ISB 2001 shows promising results in trial
Ichnos Glenmark Innovation, a clinical stage biotechnology company focused on oncology, has announced promising results for an innovative drug used for the treatment of relapsed or refractory multiple myeloma (RRMM), a rare form of blood cancer that affects plasma cells in bone marrow. Coded ISB 2001, the drug demonstrated an overall response rate (ORR) of 79% in a Phase 1 global study based on finding from patients who were administered a recommended dose. Patients who had exhausted other advanced treatments, such as CAR-T cell therapy and bi-specific antibodies, also showed encouraging results when given the drug. IGI is an alliance between the New York-based scientific research group Ichnos Sciences and Indian drug maker Glenmark. Senior haematologists say that the drug could potentially be an important candidate in the treatment of patients - who exhaust other therapy options due - to its unique mechanism of engaging the body's T cells (that are a vital part of the immune system) along with the attacking two sites on the tumour cell. Dr Shyam Rathi, consultant, clinical hematology, PD Hinduja Hospital & Medical Research Centre in Mumbai, said: 'It can definitely be a game changer in treatment of multiple myeloma which keeps relapsing thus exhausting treatment options quickly. This new drug looks very attractive because it targets two different sites on the cancer cell and it engages the body's own T-cells.' 'We have existing bi-specific antibodies where the target is only one antigen and they develop resistance very fast. However, ISB 2001 targets the two sites on the cancer cell and we expect some better results. It looks exciting in the future.' In lay terms, ISB 2001 binds to three sites on the cancer tumour. First, the ISB 2001 activates the CD-3 T-lymphocytes, which are the cells that have the natural attacking power against tumour cells. Next, it binds to two additional sites. The first is BCMA (a protein found on myeloma cells), which is the target for bi-specific antibodies but there is also CD38, which is the binding site of the widely prescribed drug called daratumumab, branded as Darzalex by Johnson & Johnson. Glenmark, which is pinning a lot of hopes on the new drug, is in advanced talks with multiple global Big Pharma companies for a licensing deal, Chairman and Managing Director Glenn Saldanha told analysts over an earnings call recently. 'The discussions are progressing really well, and we anticipate a positive outcome very quickly,' said Saldhana. He said a deal for ISB 2001 will 'really be transformational for Glenmark' and 'will overshadow anything else that we are doing in the near term.' 'You should see some visibility around a licensing deal pretty quickly.' Last year Ichnos and Glenmark entered into a partnership for discovery of cutting-edge therapies, specifically to treat blood related cancers and malignancies like multiple myeloma. The global market for multiple myeloma treatment is seeing a surge. The business for such drugs is expected to rise to $33 billion by 2030, up from $23.5 billion in 2023,according to Bloomberg Intelligence estimates. Hang Quach, professor of haematology at the University of Melbourne noted that the data presented on ISB 2001 highlighted the 'remarkable anti-myeloma activity of this first-in-class trispecific antibody-T cell engager in heavily pre-treated RRMM patients' including those who have exhausted other approved therapies. According to Quach, ISB 2001 has the potential 'to redefine the treatment landscape for multiple myeloma, offering new hope for patients with limited therapeutic options.' The drug demonstrated a favourable safety profile throughout the dose-escalation phase, with no dose-limiting toxicities (DLTs) reported.
&w=3840&q=100)
Business Standard
3 days ago
- Health
- Business Standard
Glenmark's cancer drug shows strong results in early trial for Myeloma
Glenmark Pharmaceuticals' arm, Ichnos Glenmark Innovation (IGI), shared encouraging early results from a new cancer drug being tested on patients with a difficult form of blood cancer—relapsed or refractory multiple myeloma (RRMM). The results were presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. The drug, called ISB 2001, is the first of its kind to target three markers (BCMA, CD38, and CD3) in a single treatment and has shown strong response rates in patients who have already undergone multiple prior therapies. In the dose-escalation stage of the trial, 35 patients were treated, most of whom had received a median of six prior therapies. Among 33 patients who received active doses (50 micrograms and above), the overall response rate (ORR) was 79 per cent, and 30 per cent achieved a complete or near-complete response. Safety data showed that cytokine release syndrome (CRS) occurred in 69 per cent of patients, mostly at Grade 1 severity. Four patients experienced Grade 2 CRS, and no cases of severe CRS or dose-limiting toxicities were reported. One patient experienced a mild neurological side effect, and infection rates remained low. The trial is continuing with a dose-expansion phase to determine the recommended Phase 2 dose and the optimal dosing schedule. According to Professor Hang Quach of the University of Melbourne and St Vincent's Hospital, ISB 2001 showed activity in patients who had previously received multiple treatment types, including T-cell redirecting and BCMA-targeted therapies. Lida Pacaud, Chief Medical Officer at IGI, said the current focus is on identifying the appropriate dose and expanding the trial to a broader patient population.
Mint
3 days ago
- Business
- Mint
Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial
Mumbai: Ichnos Glenmark Innovation (IGI), a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, on Monday shared promising results from an ongoing phase-1 trial of ISB 2001, a novel drug targeting relapsed or refractory multiple myeloma. The data, presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), showed an overall response rate (ORR) of 74% in heavily pre-treated patients. Refractory multiple myeloma refers to cases where the cancer does not respond or stops responding to treatment. Multiple myeloma is a rare, incurable blood cancer affecting plasma cells. While several therapies have been approved in recent years, most patients eventually relapse or become resistant, leaving limited treatment options. ISB 2001 is being developed by IGI to address this unmet need, particularly in patients who have previously received T-cell–based therapies such as CAR T-cells or bispecific antibodies. It is a first-in-class tri-specific antibody designed to simultaneously target BCMA, CD38, and CD3—three proteins associated with multiple myeloma. The drug aims to overcome resistance mechanisms seen with earlier-generation immunotherapies, while minimizing off-tumour toxicity. The phase-1 trial, known as TRIgnite-1, is evaluating the drug's safety and efficacy in patients who have exhausted standard treatment options. The latest data, from the full dose-escalation phase, covered 35 patients with a median of six prior lines of therapy. The overall response rate was 74%. 'The high response rates and low safety concerns demonstrated in the dose-escalation portion of the TRIgnite-1 study, conducted in a heavily pre-treated population across multiple types of therapies, reinforce the promise of ISB 2001 as a potential new treatment for patients,' said Lida Pacaud, M.D., chief medical officer at IGI. 'As we advance to the second part of the TRIgnite-1 study, our focus is now on defining the recommended dosing schedule and evaluating ISB 2001 in a larger population of heavily pre-treated RRMM patients, where we hope to observe similarly impressive treatment responses and tolerability,' Pacaud said. Among patients receiving higher, active dose levels (≥50 µg/kg), the ORR rose to 79%, with 30% achieving complete or stringent complete responses. Patients who had not previously received T-cell–based treatments saw an ORR of 84%. Even among those with prior exposure to CAR T or CD38-targeted therapies, response rates remained strong, ranging from 71% to 73%. The safety profile of ISB 2001 was favourable, with no dose-limiting toxicities reported. The most common side effect was cytokine release syndrome (CRS), seen in 69% of patients—mostly mild (Grade 1), with only four cases classified as moderate (Grade 2). There were no severe neurological adverse events. The market for multiple myeloma is projected to grow to about $33 billion by 2030, according to estimates by Bloomberg Intelligence. The trial has now entered its dose-expansion phase, which will determine the recommended Phase 2 dose and optimal dosing schedule. ISB 2001 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in 2023 and recently received Fast Track status, underscoring the agency's recognition of its potential.
Time of India
7 days ago
- Automotive
- Time of India
NHAI begins trial runs on new tunnel connecting Dwarka Expressway to IGI airport and NH-48
New Delhi: Just a few kilometres beyond the towering Shiv Murti near the Delhi-Gurgaon border in Mahipalpur, a small group of men in safety vests waved down vehicles, directing them into the gleaming new tunnel. As drivers cautiously inched forward, a voice message played over the speakers: "Welcome to the tunnel. Drive safe. Have a good journey." On Thursday, National Highways Authority of India (NHAI) began trial runs on a new tunnel connecting Dwarka Expressway to Indira Gandhi International (IGI) airport and NH-48. The trial, scheduled between 12pm and 3pm, aims to ease congestion on Delhi-Gurgaon Expressway and provide a faster route for commuters travelling between Gurgaon, Dwarka and the airport. The smooth tarmac stretched out ahead, with the speed limit for four-wheelers raised to 80kmph. Inside the tunnel, the walls were an explosion of colour, with murals depicting the culture of several states like Punjab, Gujarat, Chhattisgarh and Manipur, apart from Delhi. There were also depictions of the Indian Parliament, as well as murals of Mahatma Gandhi and other historical figures. The new link is the longest and widest urban road tunnel in India, according to officials. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký Undo The 5.1km tunnel comprises two segments -- a main 3.6km, eight-lane tunnel connecting Dwarka Expressway to IGI airport, and a 1.5km, two-lane tunnel linking Dwarka Expressway to NH-48 towards Gurgaon. An NHAI official said all electrical, mechanical and civil works related to the tunnel have been completed. "Once the trial -- expected to last at least three days -- is over, the inauguration will take place soon," he added. Traffic police also expect some respite on NH-48 after the tunnel is opened to the public. DCP, New Delhi range, Rajeev Kumar, said, "For those going from Delhi to Gurgaon, the new tunnel will provide relief in traffic. It will be an alternative route to the existing one, especially for nearby residents. Further, if people are coming from Jaipur, Sohna or Southern Peripheral Road, they could use the new tunnel via Dwarka Expressway for a faster, smoother ride to the airport. " The project is part of Phase 4 of the Rs 9,000-crore, 29km-long Dwarka Expressway, which runs from Mahipalpur in Delhi to Kherki Daula in Gurgaon. Of the total stretch, 18.9km fall in Haryana and 10.1km in the national capital. Once operational, the tunnel is expected to streamline travel between key areas, such as Gurgaon, Vasant Kunj, Dwarka and Alipur.
Hindustan Times
29-05-2025
- Business
- Hindustan Times
‘IGI Airport ranks 10th in the Asia-Pacific and Middle East region': DIAL
Delhi's IGI Airport has secured the 10th spot in the Asia-Pacific and Middle East region for 'seamless' connectivity, airport operator Delhi International Airport Limited (DIAL) said on Wednesday. IGI is the only Indian airport in the top 10 list, it said. The rankings have been released by the Airports Council International Asia-Pacific and Middle East. 'This milestone reflects our continuous focus on enhancing the passenger experience and maintaining the highest standards,' said DIAL chief executive officer Videh Kumar Jaipuriar. A DIAL spokesperson said the rankings were a recognition of IGI offering seamless connectivity to 153 destinations — 81 domestic and 72 international with robust infrastructure, innovative passenger services, and efficient transfer processes that have made it a preferred gateway for travellers across Asia and beyond. 'As part of its Phase 3A expansion project, DIAL has doubled the International-to-International transfer area, stepping up capacity and making transfers easier for passengers,' the spokesperson said, adding that the airport has also introduced new biometric registration kiosks for e-visa holders. 'Delhi connects to 88% of India's long-haul destinations and operates 56% of all India-origin long-haul weekly flights. 42% of all long-haul passengers from India choose Delhi as their travel gateway,' the spokesperson added. Dubai International Airport topped this year's Hub Connectivity Index, with Shanghai Pudong and Hamad International Airports next.
